drugset / Trial / NCT02990403

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

NCT02990403

Phase 4 Unknown 500 enrolled Shanghai First Maternity and Infant Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.

Timeline

Start
2014-10
Primary completion
2017-06-10
Completion
2018-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 75 mg Oral
Subject Aspirin Small molecule 100 mg Oral
Subject Dydrogesterone Other / unclassified 20 mg Oral
Subject Dydrogesterone Other / unclassified 30 mg Oral
Subject Heparin Other / unclassified 4100 iu Subcutaneous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 300 mg/kg Intravenous
Subject Prednisone Other / unclassified 5 mg Oral
Subject Prednisone Other / unclassified 10 mg Oral